Toshiya Osanai

Oct 16, 2024 | digitalcommons.library.tmc.edu | Kiyohiro Houkin |Toshiya Osanai |Shinichiro Uchiyama |Kazuo Minematsu

IMPORTANCE: Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow-derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. OBJECTIVE: To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset.